Across TCGA pan-cancer cohorts, HIGD1AP16 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of HIGD1AP16’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where HIGD1AP16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HIGD1AP16 is over-expressed in tumor, although a few such as LUAD and KIRC show the opposite, repressed pattern.

CHOL, COAD, and LUAD are the cancer types where HIGD1AP16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HIGD1AP16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	II,III,IV	+0.640	<.001	4	view →
COAD	All	All	+0.152	.010	4	view →
LUAD	All	III,IV	−0.330	.014	3	view →
BRCA	Female	All	+0.254	.015	2	view →
KIRC	All	IV	−0.152	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: HIGD1AP16 RNA expression & survival · all HIGD1AP16 data types